Notizia

Jan 31, 2017

AstraZeneca announces availability of Saxa / Dapa FDC in UK UK-based AstraZeneca has announced the availability of Qtern for adult patients with type 2 diabetes in the country. Quern is a fixed dose combination of saxagliptin and dapagliflozin. The tablet received marketing authorization from the European Commission...

Jan 03, 2017

Sanofi sues Novo over 'misleading' Tresiba marketing materials Sanofi has sued Novo over the Danish drugmaker’s marketing materials for Tresiba, alleging that they falsely claimed Sanofi’s competing products—blockbuster Lantus and follow-up Toujeo—won’t be available to many U.S. patients down the line. The pharma gi...